FPT-SOFTWARE
Global leading IT company FPT Software announced that its Chief Artificial Intelligence Officer, Dr. Nguyen Xuan Phong, has been listed on the 2024-2025 Artificial Intelligence 150 (AI150) list by Constellation Research, recognizing leaders pioneering AI transformation efforts around the globe. The Chief AI Officer is the only executive from a Southeast Asian enterprise to be named to this elite list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730156983/en/
(Graphic: Business Wire)
2024-2025 Artificial Intelligence 150 (AI150) is an inaugural initiative by Constellation Research, a technology research and advisory firm based in Silicon Valley and one of the world’s leaders in digital transformation and disruptive technology consulting. The AI150 celebrates top global executives leading AI transformation efforts globally, across multiple industries, and in various roles including Chief AI Officer, Chief Digital Officer, Chief Technology Officer, and Chief Executive Officer.
The selection process lasts six months, from nomination by industry leaders to extensive reference checks for real projects, leadership, mentorship abilities, and standing among colleagues and peer groups. Each leader on the AI150 demonstrates a comprehensive understanding of how the world is responding to artificial intelligence and how new technologies can be leveraged for future innovation.
The accolade is a testament to Dr. Nguyen Xuan Phong and FPT Software’s commitment to being a pioneer, practitioner, and advocate for the acceleration of Intelligence Transformation while using AI to address key business and technology challenges of global enterprises. Others featured in the 2024-2025 list include executives from global technology leaders like SAP, Adobe, Google, Intel, Facebook, and Microsoft, as well as Fortune 500 enterprises such as Ford Motor, United Airlines, TotalEnergies, Merck, and Schneider Electric.
FPT Software and its parent company, FPT Corporation, have over a decade of experience in the research and development of AI solutions since the establishment of its first AI Research Lab in 2019, serving as a comprehensive research, development, and learning facility for 20,000 tech personnel. In his role, Dr. Nguyen Xuan Phong heads a robust global AI Center that drives AI research and industrial application for FPT Software’s global clients, strategizing AI integration, fostering innovation, boosting productivity, and ensuring ethical AI practices. He played an instrumental role in FPT Corporation’s global partnerships with leading AI players such as NVIDIA, Mila, Landing AI, AITOMATIC, and the recent founding membership of the AI Alliance led by IBM and Meta.
“At FPT Software, we believe AI is not just about algorithms; it’s about transforming organizations, industries, and people’s lives. We are committed to expanding our AI ecosystems and embedding AI and Generative AI into all of our solutions and services, as this technology will fundamentally transform everything in business and our society,” said Dr. Nguyen Xuan Phong. “It is my pleasure to be recognized in this esteemed list, and I look forward to engaging with Constellation Research and the AI150 community to participate in global conversations and research studies on AI and business transformation.”
“In the Age of AI, we can expect AI to be infused in every part of the business. This rapidly evolving field has pioneers, policy shapers, and practitioners that will transform industries,” noted R “Ray” Wang, founder and CEO at Constellation Research. “The AI150 is our attempt of identifying a small slice of the innovators and change agents that are making substantial contributions to the advancement of this revolution.”
In addition to his work with FPT Software, Dr. Nguyen Xuan Phong is a decorated scholar with a PhD/EngD from the University of Tokyo, majoring in AI. He also made significant contributions to AI research at Hitachi in Japan and the Mila, Quebec AI Institute in Canada.
The full listing can be found here: Artificial Intelligence 150 2024 - 2025 | Constellation Research Inc.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730156983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom